| publication name | EVALUATION OF HEPATITIS B VIRUS VACCINE IMMUNOGENICITY AMONG HAEMODIALYSIS PATIENTS. |
|---|---|
| Authors | El Feky HM, *Hashish MA and **Ez El Arab MM. |
| year | 2019 |
| keywords | |
| journal | |
| volume | Not Available |
| issue | Not Available |
| pages | Not Available |
| publisher | Not Available |
| Local/International | Local |
| Paper Link | Not Available |
| Full paper | download |
| Supplementary materials | Not Available |
Abstract
This study was conducted on 50 patients with chronic renal failure on haemodialysis (HD) in end stage renal disease (ESRD) to determinate antibody response pattern after hepatitis B virus vaccination. Also, to identify factors that may affect such response. Each of patient received 3 doses of primary *vaccination; 20 μg were injected i.m. at 0,1,2 and 6 months. Antibody response levels (anti-HBs) were determined after 2 months, 13 patients (26%) were non responder, 13 were poor responder with anti-HBs ≥ 10 IU/L and 24 (48%) were good responder with anti-HBs ≥ 100 IU/L. Significant differences were observed between different response patterns regarding serum ALT, AST, ca levels, associated HCV infection and duration of HD ≤ 24 months. All these were considered as the predictors of good response to HB vaccine. In conclusion, response of HD patients to HB vaccine is inadequate. Therefore, frequent re-evaluation of seroconversion with possible booster doses of HBV vaccination if needed is recommonded.